menu
    • menu

    Company profile for Gracell Biotechnologies

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Gracell Biotechnologies is a clinical-stage biotech company. Being committed to research and development, Gracell is bringing affordable, but highly cost-effective adoptive immunotherapy to patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Gracell BiotechnologiesChina Flag
    Country
    Country
    China
    Address
    Address
    12th Floor, 926 Yishan Road, XuHui District, Shanghai
    Telephone
    Telephone
    +86-21-64031375
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gracellbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AstraZeneca completes acquisition of Gracell
    AstraZeneca completes acquisition of Gracell

    22 Feb 2024

    // INDIAN PHARMA POST

    https://www.indianpharmapost.com/news/astrazeneca-completes-acquisition-of-gracell-15300

    INDIAN PHARMA POST
    22 Feb 2024
    Share Share
    Gracell Biotechnologies Announces Shareholders™ Approval of Merger Agreement
    Gracell Biotechnologies Announces Shareholders™ Approval of Merger Agreement

    20 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/20/2831733/0/en/Gracell-Biotechnologies-Announces-Shareholders-Approval-of-Merger-Agreement.html

    GLOBENEWSWIRE
    20 Feb 2024
    Share Share
    Gracell Announces FDA Clearance of IND Application for Ph 1 of FasTCAR-T GC012F
    Gracell Announces FDA Clearance of IND Application for Ph 1 of FasTCAR-T GC012F

    29 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/29/2818728/0/en/Gracell-Biotechnologies-Announces-FDA-Clearance-of-IND-Application-for-Phase-1-Clinical-Trial-of-FasTCAR-T-GC012F-as-Early-Line-Treatment-of-Multiple-Myeloma.html

    GLOBENEWSWIRE
    29 Jan 2024
    Share Share
    AstraZeneca to buy China's Gracell Biotechnologies in $1.2 bln deal
    AstraZeneca to buy China's Gracell Biotechnologies in $1.2 bln deal

    27 Dec 2023

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html

    PRESS RELEASE
    27 Dec 2023
    Share Share
    Gracell Announces NMPA Clearance for IND for Ph 1/2 Trial of FasTCAR-T GC012F
    Gracell Announces NMPA Clearance for IND for Ph 1/2 Trial of FasTCAR-T GC012F

    21 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/21/2799883/0/en/Gracell-Biotechnologies-Announces-China-NMPA-Clearance-for-IND-Application-for-Phase-1-2-Clinical-Trial-of-FasTCAR-T-GC012F-for-the-Treatment-of-Refractory-Systemic-Lupus-Erythemat.html

    GLOBENEWSWIRE
    21 Dec 2023
    Share Share
    Biotech CAR-T roundup: Autolus, Gracell tout early-stage data at #ASH23
    Biotech CAR-T roundup: Autolus, Gracell tout early-stage data at #ASH23

    12 Dec 2023

    // Max Gelman ENDPTS

    https://endpts.com/biotech-car-t-roundup-autolus-gracell-tout-early-stage-data-at-ash/

    Max Gelman ENDPTS
    12 Dec 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search